Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study.
Roozen GVT, Prins MLM, van Binnendijk R, den Hartog G, Kuiper VP, Prins C, Janse JJ, Kruithof AC, Feltkamp MCW, Kuijer M, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Roozen GVT, et al. Among authors: prins mlm. Ann Intern Med. 2022 Dec;175(12):1771-1774. doi: 10.7326/M22-2089. Epub 2022 Oct 25. Ann Intern Med. 2022. PMID: 36279543 Free PMC article. No abstract available.
Patients' Perspectives and Feasibility of Home Monitoring in Acute Care: The AcuteCare@Home Flash Mob Study.
Weijers J, Prins MLM, van Dam DGHA; AcuteCare@Home Study Group; van Nieuwkoop C, Alsma J, Haak HR, V Uffen JW, Kaasjager KAH, Kremers MNT, Nanayakkara PWB, Stassen PM, Groeneveld GH. Weijers J, et al. Among authors: prins mlm. Telemed J E Health. 2024 Oct;30(10):2563-2572. doi: 10.1089/tmj.2024.0166. Epub 2024 Jun 28. Telemed J E Health. 2024. PMID: 38938204
Coagulation and inflammatory response after intramuscular or intradermal mRNA-1273 SARS-CoV-2 vaccine: secondary analysis of a randomized trial.
van Dijk WJ, Prins MLM, Roukens AHE, Roozen GVT, Roestenberg M, Visser LG, van Hylckama Vlieg A, Rosendaal FR. van Dijk WJ, et al. Among authors: prins mlm. Res Pract Thromb Haemost. 2024 Apr 24;8(3):102419. doi: 10.1016/j.rpth.2024.102419. eCollection 2024 Mar. Res Pract Thromb Haemost. 2024. PMID: 38779329 Free PMC article.
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose.
Roozen GVT, Prins MLM, Prins C, Janse JJ, de Gruyter HLM, Pothast CR, Huisman W, Koopman JPR, Lamers OAC, Kuijer M, Myeni SK, van Binnendijk RS, Hartog GD, Heemskerk MHM, Jochems SP, Feltkamp MCW, Kikkert M, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Roozen GVT, et al. Among authors: prins mlm. Clin Microbiol Infect. 2024 Jul;30(7):930-936. doi: 10.1016/j.cmi.2024.03.028. Epub 2024 Mar 28. Clin Microbiol Infect. 2024. PMID: 38552793 Free article. Clinical Trial.
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial.
Prins MLM, Roozen GVT, Pothast CR, Huisman W, van Binnendijk R, den Hartog G, Kuiper VP, Prins C, Janse JJ, Lamers OAC, Koopman JPR, Kruithof AC, Kamerling IMC, Dijkland RC, de Kroon AC, Azimi S, Feltkamp MCW, Kuijer M, Jochems SP, Heemskerk MHM, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Prins MLM, et al. NPJ Vaccines. 2024 Jan 2;9(1):1. doi: 10.1038/s41541-023-00785-w. NPJ Vaccines. 2024. PMID: 38167735 Free PMC article.
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.
Prins MLM, van der Plas JL, Vissers MFJM, Berends CL, Tresch G, Soergel M, Fernández E, van den Berge N, Duijsings D, Zitt C, Stavropoulou V, Zimmermann M, Drake RF, Burggraaf J, Groeneveld GH, Kamerling IMC. Prins MLM, et al. Br J Clin Pharmacol. 2023 Mar;89(3):1105-1114. doi: 10.1111/bcp.15560. Epub 2022 Oct 24. Br J Clin Pharmacol. 2023. PMID: 36214216 Free PMC article. Clinical Trial.